Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05180357 · ClinicalTrials.gov registry record
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 273
- Enrollment target
NCT05180357 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 273 participants.
The verdict
NCT05180357 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 273 participants
- Enrollment target
Study Summary
The purpose of this observational study is to describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.
Interventions
- OTHER FASENRA(benralizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2021-11-23 |
| Est. Completion | 2022-10-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05180357
The ClinicalTrials.gov registry entry for NCT05180357 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 273 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FASENRA(benralizumab) is the first listed.
NCT05180357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05180357 about?
NCT05180357 is a clinical study titled "RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.". The purpose of this observational study is to describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.
What is the current status of trial NCT05180357?
This trial is currently completed. The enrollment target is 273 participants. The study started on 2021-11-23. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT05180357?
The interventions under investigation include: FASENRA(benralizumab) (OTHER).
Who is sponsoring clinical trial NCT05180357?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.